{"id":4343,"date":"2024-03-19T15:55:46","date_gmt":"2024-03-19T15:55:46","guid":{"rendered":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/03\/19\/engrail-therapeutics-raises-157-million-in-funding-from-f-prime-capital-others\/"},"modified":"2024-03-19T15:55:46","modified_gmt":"2024-03-19T15:55:46","slug":"engrail-therapeutics-raises-157-million-in-funding-from-f-prime-capital-others","status":"publish","type":"post","link":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/03\/19\/engrail-therapeutics-raises-157-million-in-funding-from-f-prime-capital-others\/","title":{"rendered":"Engrail Therapeutics raises $157 million in funding from F-Prime Capital, others"},"content":{"rendered":"
\"Engrail<\/div>


\n<\/p>\n

Engrail Therapeutics<\/a>, a clinical stage company developing therapies against central nervous system (CNS) disorders on Tuesday said it has raised $157 million in Series B financing<\/a> round co-led by healthcare focused venture capital<\/a> firms F-Prime Capital<\/a>, Forbion, and growth equity investor Norwest Venture Partners.<\/p>\n

The funding round saw participation of investors such as Eight Roads Ventures, RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysios Capital, Longwood Fund, and existing founding investor Pivotal Life Sciences.<\/p>\n

<\/p>\n

\n
\n

Elevate Your Tech Prowess with High-Value Skill Courses<\/h3>\n\n\n\n\n\n\n
Offering College<\/th>\nCourse<\/th>\nWebsite<\/th>\n<\/tr>\n
MIT<\/td>\nMIT Technology Leadership and Innovation<\/td>\nVisit<\/a><\/td>\n<\/tr>\n
Indian School of Business<\/td>\nISB Product Management<\/td>\nVisit<\/a><\/td>\n<\/tr>\n
IIM Kozhikode<\/td>\nIIMK Advanced Data Science For Managers<\/td>\nVisit<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

<\/div>\n

The proceeds of the fund raise will help to support advancement of Engrail\u2019s pipeline for neuropsychiatric and neurodevelopmental disorders<\/p>\n

The company’s lead pipeline asset, ENX-101, is a selective GABA modulator that helps to treat people suffering from anxiety, pain and other indications.<\/p>\n

ENX-101, is developed as a potential non-addictive and safe treatment alternative to current therapy benzodiazepines, which is a non-selective GABA modulator with risk of side effects like sedation, cognitive impairment and risk of addiction.<\/p>\n

Engrail was founded in 2019 by Vikram Sudarsan<\/a>, and Stephen Cunningham.<\/p>\n

\n
\n
\n
\n

Discover the stories of your interest<\/h3>\n<\/div>\n
<\/span><\/span><\/div>\n<\/div>\n<\/section>\n<\/div>\n


Sudarsan was a former Cipla<\/a> executive who headed Cipla Technologies<\/a> where he built a pipeline of branded products to treat CNS disorders and respiratory diseases. Prior to that, Sudarsan headed strategy at Cipla New Ventures<\/a>.The Engrail team is primarily based in the US, with team members in India and Europe.<\/p>\n

“We look forward to completing our ongoing ENX-102 phase 2 study in generalized anxiety disorder and advancing the rest of our pipeline into clinical development,\u201d Vikram Sudarsan, president and CEO of Engrail Therapeutics. <\/p>\n

Engrail had raised $64 million in August 2021. In total, it has raised $220 million in capital<\/p>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Engrail Therapeutics, a clinical stage company developing therapies against central nervous system (CNS) disorders on Tuesday said it has raised $157 million in Series B financing round co-led by healthcare focused venture capital firms F-Prime Capital, Forbion, and growth equity investor Norwest Venture Partners. The funding round saw participation of investors such as Eight Roads […]<\/p>\n","protected":false},"author":2,"featured_media":4344,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"tdm_status":"","tdm_grid_status":"","fifu_image_url":"https:\/\/img.etimg.com\/photo\/88591548.cms","fifu_image_alt":"","footnotes":""},"categories":[607],"tags":[2292,7512,7518,7517,7519,7513,7516,7521,2801,2458,506,7514,7520,2285,7515],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/4343"}],"collection":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/comments?post=4343"}],"version-history":[{"count":1,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/4343\/revisions"}],"predecessor-version":[{"id":4345,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/4343\/revisions\/4345"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media\/4344"}],"wp:attachment":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media?parent=4343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/categories?post=4343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/tags?post=4343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}